CAS: 105149-04-0; Osaterone

该化合物是一种合成类固醇,主要作为抗体,其特点是能够抑制作为男性荷尔蒙的雄性激素和机器人的动作,从而影响各种生理过程;Osaterone经常用于兽医,特别是治疗动物过多和机器人含量的条件;其行动机制涉及对受体和受体具有约束力,防止自然激素施加其影响;该化合物通常以受控的方式管理特定健康问题,其药用动力学特征可能因管理途径而不同;安全性和功效特征是其使用中的基本考虑因素,与任何药剂一样;此外,继续研究其潜在应用和影响,有助于了解其在兽医学和可能的人类医学方面的作用;与任何化学物质一样,妥善处理和遵守安全准则对于减少与使用有关的任何风险至关重要.

结构式图片

MSDS等安全信息

    上下游产品

    5-Ethyl-2-Methylpyridine-N-Oxide 105149-00-6
    17-Acetoxypregna-1,4,6-Triene-3,20-Dione 2668-75-9

    合成工艺路线路线简述

      📜17-Acetoxypregna-1,4,6-Triene-3,20-Dione置于吡啶,盐酸,Sodium Hydroxide,Sodium Methylate,Potassium Acetate,Sodium Acetate,臭氧,间氯过氧苯甲酸,苯酚体系中,用 四氢呋喃,甲醇,氯仿,N,N-二甲基甲酰胺 用作溶剂,化学反应 46.09H,反应生成奥沙特隆
      参考文献:Antiandrogen. I. 2-Azapregnane And 2-Oxapregnane Steroids.
      标题:Antiandrogen. I. 2-Azapregnane And 2-Oxapregnane Steroids.
      摘要:2-氮氯马地酮乙酸酯(5A,17-乙酰氧基-6-氯-2-氮孕-4,6-二烯-3,20-二酮),2-氧氯马地酮乙酸酯(6,17-乙酰氧基-6-氯-2-氧孕-4,6-二烯-3,20-二酮)及其衍生物被制备为潜在的抗雄激素剂.生物评估显示,在去势雄性大鼠中,5A和6表现出强大的抗雄激素活性.
      Doi:10.1248/cpb.40.935

      海关参考信息

      专利信息


      专利号:US-12391691-B2
      优先权日:2018-11-16
      标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
      发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
      权利人:AMGEN INC
      摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

      专利号:US-2025206736-A1
      优先权日:2019-11-14
      标题 :Synthesis of kras g12c inhibitor compound
      发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
      权利人:AMGEN INC
      摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

      专利号:US-8734846-B2
      优先权日:2008-06-16
      标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
      发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
      权利人:BIND BIOSCIENCES INC
      摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

      专利号:US-2013035307-A1
      优先权日:2010-01-26
      标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
      发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
      权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
      摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

      专利号:US-2008214827-A1
      优先权日:2004-02-03
      标 题:Synthesis of Cyanoimino-Benzoimidazoles
      发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
      权利人:EURO CELTIQUE SA
      摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

      专利号:US-9220714-B2
      优先权日:2006-03-16
      标 题 :Nitrofuran compounds for the treatment of cancer and angiogenesis
      发明人:SAULNIER SHOLLER GISELLE L; SWAMY NARASIMHA; KALKUNTE STAYAN; SINGH RAKESH K; BRARD LAURENT; KIM KYU KWANG
      权利人:WOMEN AND INFANTS HOSPITAL OF RHODE ISLAND; UNIV BROWN; WOMEN AND INFANTS HOSPITAL RHODE ISLAND
      摘要:The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Albouy M, Sanquer A, Maynard L, Eun HM. Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs. Vet Rec. 2008 Aug 9;163(6):179-83. doi: 10.24425/pjvs.2018.125601. doi: 10.1111/rda.12297. Review. doi: 10.1638/2015-0215.1.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知